Golimumab
Golimumab is a pharmaceutical drug with 63 clinical trials. Currently 7 active trials ongoing. Historical success rate of 87.5%.
Success Metrics
Based on 42 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
11
Mid Stage
35
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
85.7%
42 of 49 finished
14.3%
7 ended early
7
trials recruiting
63
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Clinical Trials (63)
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes
CHronic Nonbacterial Osteomyelitis International Registry
Golimumab for Adherence in Rheumatoid Arthritis
Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 63